BridgeBio Pharma Is Maintained at Outperform by Evercore ISI Group

Dow Jones02:05 · Ratings

Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $50

Futu NewsDec 23 22:32 · Ratings

Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46

Futu NewsDec 19 07:32 · Ratings

Optimistic Buy Rating for BridgeBio Pharma Due to Strong Launch and Strategic Initiatives

TipRanksDec 18 13:25 · Ratings

H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $49

Futu NewsDec 16 20:31 · Ratings

BridgeBio Pharma Analyst Ratings

BenzingaDec 16 20:20 · Ratings